HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

NEXT STORY
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
PREV STORY
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

author_avatar
NASDAQ Market News

American College of Rheumatology COVID-19 Vaccine Guidance Recommends Vaccination, Addresses Immunosuppressant Drugs & Patient Concerns

author_avatar
NASDAQ Market News

Ramsay Santé strengthens its primary care activities with the acquisition of the Danish company WeCare

author_avatar
NASDAQ Market News